

Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan

Takeji Umemura,¹ Eiji Tanaka,¹ Kendo Kiyosawa,^{1,a} Hiromitsu Kumada,² and the Japan de novo Hepatitis B Research Group^b

¹Department of Internal Medicine, Hepatology, and Gastroenterology, Shinshu University School of Medicine, Matsumoto, and ²Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen–positive patients in Japan. Because one-fourth of cases develop into fulminant hepatic failure and mortality is 100%, management of HBV reactivation in patients with resolved HBV infection should be discussed.

Reactivation of hepatitis B virus (HBV) is becoming a well-recognized complication in patients with chronic HBV infection who are undergoing cytotoxic chemotherapy or immunosuppressive therapy [1–5]. HBV reactivation has a variety of manifestations, ranging from subclinical increases in transaminase activity to severe and potentially fatal fulminant hepatic failure (FHF). Because clinical studies have demonstrated that lamivudine therapy reduces the rate of HBV reactivation and mortality [6–9], prophylactic antiviral therapy is advised for HBV carriers at the onset of chemotherapy [10].

The clearance of hepatitis B surface antigen (HBsAg) and the appearance of antibody to HBsAg, with normalization of liver function, is generally accepted as evidence of clinical and serologic recovery from acute hepatitis B. However, HBV replication has been shown to persist at low levels in the liver for decades [11–13], which may explain the recent increase in the rate of HBV reactivation in patients with resolved infection during or after chemotherapy and transplantation [1, 5, 14–

16]. Although reactivation led to FHF and even death in some cases [17–22], the incidence of and mortality associated with HBV reactivation have not been fully clarified in this context. Recently, a prospective study [23] from Hong Kong revealed that 3.3% of HBsAg-negative patients developed HBV reactivation after chemotherapy. In Japan, because ~20% of individuals are positive for at least 1 HBV marker [24], HBV reactivation during or after immunosuppressive treatment may become a critical issue in the near future. Thus, we investigated the mortality associated with and prevalence and clinical significance of HBV reactivation in Japanese patients with resolved HBV infection in a multicenter, cross-sectional study.

Methods. In 2005, we sent a questionnaire to 230 hospitals certified by the Japan Society of Hepatology; this included questions about patients who had become newly positive for serum HBsAg from January 2000 through December 2004 [25]. A total of 1239 patients were registered by 93 hospitals (40%). Of those patients, 55 were recorded as having experienced HBV reactivation after having resolved HBV infection, and the remaining 1184 patients were classified as having acute hepatitis B. Sixty-three (68%) of 93 hospitals responded to a second survey and provided information on 552 patients enrolled in this study; 23 of these patients developed HBV reactivation, and 529 had acute hepatitis B.

HBV reactivation was defined (according to a slight modification of the report by Hui et al. [23]) as a decrease in the level of antibody to HBsAg that was associated with the reappearance of HBsAg, a 3-fold elevation of serum alanine aminotransferase (ALT) level above normal, and detection of HBV DNA in serum during or after chemotherapy. The diagnoses of acute hepatitis B and FHF were defined as reported elsewhere [26]. Patients with other liver diseases were excluded. Serum HBV markers were determined as reported elsewhere [26]. Serum levels of HBV DNA were determined with use of Amplicor HBV Monitor kits (Roche Diagnostics) at each hospital when the patients were admitted. HBV genotypes were determined with use of the PCR-invader method, with genotype-specific probes [27]. This study was approved by the ethics committees of appropriate institutional review boards. Informed consent was obtained from each patient in accordance with the Helsinki Declaration.

The Mann-Whitney *U* test was used to analyze continuous variables. The χ^2 test with Yate's correction was used for analysis of categorical data. In cases in which the number of patients was <5, Fisher's exact test was used. $P \leq .05$ was considered to

Received 25 March 2008; accepted 16 May 2008; electronically published 21 July 2008.

^a Present affiliation: Nagano Red Cross Hospital, Nagano, Japan.

^b Members of the study group are listed at the end of the text.

Reprints or correspondence: Dr. Takeji Umemura, Dept. of Internal Medicine, Gastroenterology, and Hepatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan (umemura@shinshu-u.ac.jp).

Clinical Infectious Diseases 2008;47:e52–6

© 2008 by the Infectious Diseases Society of America. All rights reserved.

1058-4838/2008/4705-00E2\$15.00

DOI: 10.1086/590968

be statistically significant. Statistical analyses were performed using SPSS, version 15.0J (SPSS).

Results. We first compared the demographic, clinical, and virologic features of the 23 patients who experienced HBV reactivation with those of the 529 patients with acute hepatitis B (table 1). The reactivation group had a significantly higher median age and median serum HBV DNA level ($P < .001$) and significantly lower peak ALT and albumin levels ($P < .001$). Although HBV genotype was not determined for one-half of the patients with acute hepatitis B, marked differences in the distribution of genotypes were seen; HBV type A occurred less frequently ($P = .003$) among patients with HBV reactivation than among those with acute hepatitis. However, HBV type B occurred more frequently among patients with HBV reactivation ($P < .001$).

FHF was more common among patients with HBV reactivation than among those with acute hepatitis ($P = .048$). Of the 23 cases of HBV reactivation, 6 (26%) resulted in liver-related death, 11 (48%) resolved, and 6 (26%) led to chronic hepatitis B. In contrast, of the 529 cases of acute hepatitis B, 490 (93%) were self-limited, 16 (3%) became chronic, and 21 (4%) resulted in death. These results revealed that liver-related mortality was significantly higher in the group with HBV reactivation than in the group with acute hepatitis ($P < .001$).

We then compared the clinical features of FHF between the groups (table 2). Patients with HBV reactivation had a higher median age, significantly lower peak ALT levels ($P = .006$),

higher HBV DNA levels ($P = .035$), and higher mortality ($P = .031$) than did patients with acute hepatitis B.

Malignant lymphoma-associated morbidity was significantly higher among patients with HBV reactivation who developed FHF than among those who did not develop FHF (table 3). A rituximab-containing treatment regimen was administered to all patients who experienced FHF, compared with only 4 (22%) of 18 patients who did not experience FHF ($P = .004$). Lamivudine was administered to 16 (89%) of 18 patients who did not experience FHF and to all patients who experienced FHF at 7 and 20 days after hospital admission, respectively; this suggests that lamivudine treatment could not prevent FHF after HBV reactivation. Eventually, liver-related mortality occurred exclusively in patients who experienced FHF. There were no statistically significant differences between the 2 subgroups regarding HBV markers.

Discussion. Although a prospective study by Hui et al. [23] revealed that the incidence of HBV reactivation among HBsAg-negative patients after chemotherapy was 3.3%, there are no data available on HBV reactivation in Japan. In our nationwide cross-sectional study, a total of 552 newly HBsAg-positive patients were registered from 63 tertiary care hospitals. Overall, HBV reactivation was found in 4% of patients with resolved infection after chemotherapy. Serum and liver samples were not available before chemotherapy for most of these patients; therefore, we were unable to prove specifically whether reactivation was a result of occult or acute HBV infection. However,

Table 1. Demographic and clinical characteristics of patients with hepatitis B virus (HBV) reactivation, compared with those of patients with acute hepatitis B.

Characteristic	Patients with HBV reactivation	Patients with acute hepatitis B	<i>P</i>
Age, median years (95% CI)	63 (39–83)	33 (19–64)	<.001
Male sex	14/23 (61)	374/529 (71)	NS
Peak ALT level, median IU/L (95% CI)	929 (137–2441)	2300 (299–6626)	<.001
Peak bilirubin level, median mg/dL (95% CI)	10.3 (0.3–58.6)	6.4 (1.0–23.7)	NS
Lowest albumin level, median g/dL (95% CI)	3.2 (2.1–3.7)	3.6 (2.7–4.2)	<.001
Most prolonged PT%, median % (95% CI)	65.0 (10.2–121.4)	75.0 (11.0–103.1)	NS
HBV DNA level, median log copies/mL (95% CI)	7.5 (4.0 to >7.6)	5.5 (2.6 to >7.6)	<.001
Genotype			
A	0/19 (0)	57/232 (25)	.003
B	8/19 (42)	27/232 (12)	<.001
C	11/19 (58)	141/232 (61)	NS
Other	0/19 (0)	7/232 (3)	
Treatment			
Lamivudine	20/23 (87)	118/529 (22)	<.001
IFN	5/23 (22)	12/529 (2)	<.001
Fulminant hepatic failure	5/23 (22)	45/529 (9)	.048
Liver-related death	6/23 (26)	21/529 (4)	<.001

NOTE. Data no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; NS, not statistically significant; PT, prothrombin time.

Table 2. Demographic and clinical characteristics of patients with hepatitis B virus (HBV) reactivation who experienced fulminant hepatic failure (FHF), compared with those of patients with acute hepatitis B who experienced FHF.

Characteristic	Patients with FHF		P
	With HBV reactivation	With acute hepatitis B	
Age, median years (95% CI)	63 (47–64)	48 (18–72)	.029
Male sex	3/5 (60)	26/45 (58)	NS
Peak ALT level, median IU/L (95% CI)	907 (359–1823)	5995 (589–11,858)	.006
Peak bilirubin level, median mg/dL (95% CI)	20.8 (10.2–45.7)	9.9 (4.9–30.5)	.099
Lowest albumin level, median g/dL (95% CI)	2.6 (2.1–3.0)	2.9 (1.9–3.9)	NS
Most prolonged PT%, median % (95% CI)	22.0 (8.7–32.3)	16.0 (0.2–37.0)	NS
HBV DNA level, median log copies/mL (95% CI)	7.6 (5.6 to >7.6)	5.7 (2.6 to >7.6)	.035
Genotype			
A	0/5 (0)	2/16 (13)	NS
B	1/5 (20)	3/16 (19)	NS
C	4/5 (80)	11/16 (69)	NS
Received lamivudine treatment	5/5 (100)	29/45 (81)	NS
Liver-related death	5/5 (100)	21/45 (47)	.031

NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; NS, not statistically significant; PT, prothrombin time.

because all patients were negative for HBsAg and positive for antibody to hepatitis B core antigen before treatment, we presumed that reactivation was occult in nature.

In our study, patients who experienced HBV reactivation were significantly older and had lower serum albumin levels, compared with patients with acute hepatitis B. The immune status of many patients may have been further decreased by cytotoxic chemotherapy. Approximately 20% of the patients who experienced HBV reactivation developed FHF. Surprisingly, mortality was 100%, implying that FHF in these cases is severe. Both the prevalence of and mortality associated with FHF were significantly higher among patients who experienced HBV reactivation than among those with acute HBV infection. Although the group with HBV reactivation also had lower albumin levels at the onset of lamivudine therapy, the development of FHF could not be predicted from this study. Thus, it is crucial to prevent FHF in patients with HBV reactivation with use of agents other than—or complimentary to—lamivudine. Unfortunately, preemptive therapy is not recommended because of the difficulties in detecting reactivation. Hui et al. [23] recommended monthly testing of HBV DNA levels and immediate antiviral therapy when levels are 100-fold the levels before chemotherapy. However, this strategy is still controversial [28, 29] and needs testing in a randomized study.

A recent study revealed that HBV type Bj and G1896A mutations were independently associated with a fulminant outcome in patients with acute HBV infection [30]. However, HBV genotype, serum HBV DNA level, or mutations in G1896A or A1762T/G1764A did not influence the development of FHF in patients who experienced HBV reactivation in this study. HBV

reactivation in patients infected with HBV genotype A was also not found in this study, which may be explained by the fact that this genotype occurs in only 1.7% of patients with chronic hepatitis B in Japan [31].

Because our study and other studies [23] have confirmed that HBV reactivation can be fatal, we need to emphasize greater testing of HBV markers, including antibody to hepatitis B core antigen, antibody to HBsAg, and HBV DNA levels before administration of chemotherapy, especially therapy containing rituximab. Patients with resolved HBV infection should be routinely monitored for liver function and HBV DNA levels, and antiviral therapy should be administered immediately when evidence of HBV reactivation is found.

In conclusion, HBV reactivation is found in 4% of newly HBsAg-positive patients with resolved HBV infection in Japan. One-fourth of cases of HBV reactivation develop into FHF, and mortality is extremely high. Because our study was unable to distinguish HBV reactivation from occult HBV infection and could not clarify whether antiviral therapy was effective, a prospective study is being planned to clarify the mechanism of HBV reactivation and the benefits of antiviral therapy.

Japan de novo Hepatitis B Research Group. Tetsuya Ishikawa (Aichi Medical University), Takaaki Otake (Asahikawa Medical University), Kunihide Ishii (Asakura Hospital), Kenichi Fukai (Chiba University), Yoichi Hiasa and Morikazu Onji (Ehime University), Yuichi Tanabe (Fukuoka City Hospital), Kozou Fujio (Fukuyama City Hospital), Tatsuro Sakata (Fukuyama Medical Center), Eiichi Tomita (Gifu Municipal Hospital), Hideki Hagiwara (Higashiosaka City General Hospital), Mikiya Kitamoto (Hiroshima Prefectural Hospital), Shoichi

Table 3. Demographic and clinical characteristics of patients with hepatitis B virus (HBV) reactivation who did and did not experience fulminant hepatic failure (FHF).

Characteristic	Patients with HBV reactivation		P
	Experienced FHF (n = 5)	Did not experience FHF (n = 18)	
Age, median years (95% CI)	63 (47–64)	63 (39–78)	NS
Male sex	3 (60)	11 (61)	NS
Peak ALT level, median IU/L (95% CI)	907 (359–1823)	1016 (124–2524)	NS
Peak bilirubin level, median mg/dL (95% CI)	20.8 (10.2–45.7)	7.6 (0.3–24.9)	.094
Lowest albumin level, median g/dL (95% CI)	2.6 (2.1–3.0)	3.3 (2.2–3.6)	.015
Most prolonged PT%, median % (95% CI)	22.0 (8.7–32.3)	77.5 (18.0–101.8)	<.001
ALT level, ^a median IU/L (95% CI)	176 (83–1035)	266 (58–1690)	NS
Bilirubin level, ^a median mg/dL (95% CI)	0.7 (0.4–7.2)	0.7 (0.3–13.6)	NS
Albumin level, ^a median g/dL (95% CI)	3.4 (2.5–3.5)	3.9 (2.8–4.5)	.035
PT%, ^a median % (95% CI)	42.2 (16.4–46.4)	83.7 (38.7–123.5)	NS
HBV DNA level, median log copies/mL (95% CI)	7.6 (5.6 to >7.6)	7.5 (4.0 to >7.6)	NS
Genotype			
Bj	1 (20)	7/14 (50)	NS
C	4 (80)	7/14 (50)	NS
Mutation			
G1896A	4 (80)	5/12 (42)	NS
A1762T/G1764A	2 (40)	2/12 (17)	NS
Non-Hodgkin lymphoma	5 (100)	8 (44)	.046
Received a rituximab-containing treatment regimen	5 (100)	4 (22)	.004
Treatment			
Lamivudine	5 (100)	16 (89)	NS
IFN	1 (20)	4 (22)	NS
Liver-related death	5 (100)	1 (6)	<.001

NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; NS, not statistically significant; PT, prothrombin time.

^a Laboratory data are from the start of lamivudine therapy.

Takahashi (Hiroshima University), Yuji Oka (Hitachi General Hospital), Koichi Abe (Iwate Medical University), Makoto Oke-tani and Hirohito Tsubouchi (Kagoshima University), Akito Sakai (Kanazawa University), Mutsumi Tsuchishima (Kana-zawa Medical University), Gotaro Yamada (Kawasaki Medical University), Yoshihiro Akahane (Kofu Municipal Hospital), Akihide Masumoto (Kokura National Hospital), Hiroyuki Shi-momura (Kurashiki Central Hospital), Tatsuya Ide (Kurume University), Masahito Minami (Kyoto Prefectural University), Sawako Inoue (Kyushu University), Michimori Kono (Matsue City Hospital), Motoo Iwasa (Mie University), Naoya Murash-ima (Mishuku Hospital), Shigehiko Sainokami (Mizusawa Hos-pital), Masayuki Kurosaki Musashino Red Cross Hospital), Toru Ishikawa (Nagaoka Red Cross Hospital), Hiroshi Yatsu-hashii (Nagasaki Medical Center), Shogo Okoshi (Niigata Uni-versity), Kenji Soga (Nippon Dental University Niigata), Shi-getoshi Fujiyama (NTT West Japan Kyushu Hospital), Yuji Kato (Oita Prefectural Hospital), Tetsuo Takehara and Morikazu Seki (Osaka University), Hiromasa Yoshihara (Osaka Rosai Hospi-tal), Tadakazu Sekine (Saiseikai Kawaguchi General Hospital),

Shuichi Miyase (Saiseikai Kumamoto Hospital), Tomoteru Ka-mimura (Saiseikai Niigata Daini Hospital), Shuichi Kubo (Sais-eikai Yokohama Nanbu Hospital), Yoshiyasu Karino (Sapporo-Kosei General Hospital), Masamichi Nagasawa (Seirei Hamamatsu General Hospital), Takayoshi Ito (Showa Univer-sity), Chiaki Okuse (St. Marianna University), Akira Sato (St. Marianna University Yokohama City Seibu Hospital), Atsushi Tanaka (Teikyo University), Jong-Hon Kang (Teine Keijinkai Hospital), Yoshiyuki Ueno (Tohoku University), Yusei Ikeda (Tokyo Kosei Nenkin Hospital), Naoaki Hashimoto (Tokyo Teishin Hospital), Takuji Yamada (Tomei Atsugi Hospital), Kenji Ikeda (Toranomom Hospital), Mari Kawakami (Tottori University), Terumi Takahara (Toyama University), Sumio Ka-wata (Yamagata University), Takahiro Kodama (Yamaguchi Grand Center), and Takaaki Ikeda (Yokosuka Kyou-sai Hospital).

Acknowledgments

Financial support. Ministry of Health, Labour, and Welfare of Japan (to K.K.) and Viral Hepatitis Research Foundation of Japan (to T.U.).

Potential conflicts of interest. All authors: no conflicts.

References

1. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. *Gastroenterology* **1975**; 68:105–12.
2. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. *Lancet* **1975**; 2:528–30.
3. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. *Ann Intern Med* **1981**; 94:744–8.
4. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. *Ann Intern Med* **1982**; 96:447–9.
5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. *Gastroenterology* **1991**; 100:182–8.
6. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred pre-emptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. *Gastroenterology* **2003**; 125:1742–9.
7. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. *Ann Hematol* **2004**; 83:270–5.
8. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. *J Clin Oncol* **2004**; 22: 927–34.
9. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. *Breast Cancer Res Treat* **2004**; 88:209–15.
10. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* **2007**; 45: 507–39.
11. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. *Gastroenterology* **1992**; 103:1649–56.
12. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. *Hepatology* **1993**; 18:1313–8.
13. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. *J Clin Invest* **1994**; 93:230–9.
14. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. *Transplantation* **1998**; 66:616–9.
15. Seth P, Alrajhi AA, Kagevi I, et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. *Bone Marrow Transplant* **2002**; 30:189–94.
16. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. *Clin Infect Dis* **2005**; 41:1277–82.
17. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. *N Engl J Med* **2001**; 344:68–9.
18. Westhoff TH, Jochimsen F, Schmittl A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. *Blood* **2003**; 102:1930.
19. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. *J Infect Chemother* **2005**; 11:189–91.
20. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. *Leuk Lymphoma* **2005**; 46:1085–9.
21. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. *Intern Med* **2006**; 45:721–4.
22. Kitano K, Kobayashi H, Hanamura M, et al. Fulminant hepatitis after allogeneic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promoter region. *Eur J Haematol* **2006**; 77:255–8.
23. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* **2006**; 131:59–68.
24. Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. *Gastroenterology* **1994**; 106:1596–602.
25. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. *Intern Med* **2006**; 45:747–8.
26. Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. *J Infect Dis* **2003**; 188:1545–52.
27. Tadokoro K, Kobayashi M, Yamaguchi T, et al. Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes. *J Virol Methods* **2006**; 138:30–9.
28. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. *Clin Gastroenterol Hepatol* **2006**; 4:936–62.
29. Liu CJ, Kao JH, Chen DS. Kinetics of hepatitis B virus reactivation after chemotherapy: more questions than answers. *Gastroenterology* **2006**; 131:1656 (author reply: *Gastroenterology* 2006; 131:1657).
30. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* **2006**; 44:326–34.
31. Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. *Hepatology* **2001**; 33:218–23.